NCT06761183View on ClinicalTrials.gov

Safety and Preliminary Efficacy of NXL-001 in Patients with Ischemic Stroke

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Ischemic Stroke
Interventions
GENETIC

intracerebral stereotactic injection of NXL-001

intracerebral stereotactic injection of NXL-001: with 3 subjects in each group to receive a single stereo-tactically intracerebral injection of NXL-001 at escalating doses.

Trial Locations (1)

10070

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER